JP6856188B2 - Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞 - Google Patents

Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞 Download PDF

Info

Publication number
JP6856188B2
JP6856188B2 JP2016512083A JP2016512083A JP6856188B2 JP 6856188 B2 JP6856188 B2 JP 6856188B2 JP 2016512083 A JP2016512083 A JP 2016512083A JP 2016512083 A JP2016512083 A JP 2016512083A JP 6856188 B2 JP6856188 B2 JP 6856188B2
Authority
JP
Japan
Prior art keywords
cells
car
transduced
cell
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016512083A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016524598A (ja
Inventor
チァンファ ユー，
チァンファ ユー，
クレッグ ホフマイスター，
クレッグ ホフマイスター，
チァンホン チュ，
チァンホン チュ，
Original Assignee
オハイオ・ステイト・イノベーション・ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オハイオ・ステイト・イノベーション・ファウンデーション filed Critical オハイオ・ステイト・イノベーション・ファウンデーション
Publication of JP2016524598A publication Critical patent/JP2016524598A/ja
Application granted granted Critical
Publication of JP6856188B2 publication Critical patent/JP6856188B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
JP2016512083A 2013-05-03 2014-05-02 Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞 Active JP6856188B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361819141P 2013-05-03 2013-05-03
US61/819,141 2013-05-03
US201361876492P 2013-09-11 2013-09-11
US61/876,492 2013-09-11
PCT/US2014/036684 WO2014179759A1 (en) 2013-05-03 2014-05-02 Cs1-specific chimeric antigen receptor engineered immune effector cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019079616A Division JP2019146579A (ja) 2013-05-03 2019-04-18 Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞

Publications (2)

Publication Number Publication Date
JP2016524598A JP2016524598A (ja) 2016-08-18
JP6856188B2 true JP6856188B2 (ja) 2021-04-07

Family

ID=51844005

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016512083A Active JP6856188B2 (ja) 2013-05-03 2014-05-02 Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞
JP2019079616A Pending JP2019146579A (ja) 2013-05-03 2019-04-18 Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞
JP2021118254A Active JP7221338B2 (ja) 2013-05-03 2021-07-16 Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019079616A Pending JP2019146579A (ja) 2013-05-03 2019-04-18 Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞
JP2021118254A Active JP7221338B2 (ja) 2013-05-03 2021-07-16 Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞

Country Status (15)

Country Link
US (3) US10358494B2 (https=)
EP (2) EP3663320A1 (https=)
JP (3) JP6856188B2 (https=)
KR (1) KR102098985B1 (https=)
CN (2) CN105377897A (https=)
AU (2) AU2014259675B2 (https=)
BR (1) BR112015027567B1 (https=)
DK (1) DK2992020T3 (https=)
ES (1) ES2777940T3 (https=)
HU (1) HUE048312T2 (https=)
IL (1) IL242315B (https=)
MX (1) MX370173B (https=)
PL (1) PL2992020T3 (https=)
PT (1) PT2992020T (https=)
WO (1) WO2014179759A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105377897A (zh) * 2013-05-03 2016-03-02 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
KR102558502B1 (ko) 2014-12-05 2023-07-20 시티 오브 호프 Ｃｓ1 표적화된 키메라 항원 수용체-변형된 ｔ 세포
JP6797803B2 (ja) * 2014-12-31 2020-12-09 セルジーン コーポレイション ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法
WO2016123143A1 (en) 2015-01-26 2016-08-04 The University Of Chicago CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
CN107683289B (zh) 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
JP6849600B6 (ja) 2015-01-29 2021-06-30 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ キメラ抗原受容体、組成物及び方法
WO2016134371A2 (en) 2015-02-20 2016-08-25 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
US11045543B2 (en) 2015-04-06 2021-06-29 Cytoimmune Therapeutics, Inc. EGFR-directed car therapy for glioblastoma
US10752670B2 (en) * 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
EP3307876B1 (en) * 2015-06-10 2023-09-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
JP7010487B2 (ja) 2015-08-17 2022-03-03 ソウル大学校産学協力団 抗コチニン抗体が連結したキメラ抗原受容体およびその使用
EP4289944A3 (en) * 2015-10-08 2024-03-13 National University Corporation Tokai National Higher Education and Research System Method for preparing genetically-modified t cells which express chimeric antigen receptor
EP3402495A4 (en) * 2016-01-15 2019-06-19 Etubics Corporation METHOD AND COMPOSITIONS FOR T-CELL IMMUNOTHERAPY
EP3408297A2 (en) 2016-01-29 2018-12-05 Med Manor Organics, (P) Ltd A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
EP3433269B1 (en) 2016-03-23 2023-09-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
CN121102467A (zh) 2016-04-22 2025-12-12 克莱格医学有限公司 用于细胞免疫疗法的组合物和方法
JP7086928B2 (ja) 2016-07-25 2022-06-20 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変されたナチュラルキラー細胞を生成する方法および使用方法
US12516292B2 (en) 2016-07-25 2026-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing modified natural killer cells and methods of use
CN106279432B (zh) * 2016-08-10 2019-09-20 深圳市再生之城生物医药技术有限公司 一种vc-car分子及在清除hiv-1感染细胞中的应用
WO2018058432A1 (zh) * 2016-09-28 2018-04-05 李华顺 一种多基因重组嵌合抗原受体分子及其应用
CA3048211A1 (en) 2016-12-23 2018-06-28 Macrogenics, Inc. Adam9-binding molecules, and methods of use thereof
EP3567101A4 (en) * 2017-01-05 2020-12-02 Korea Research Institute of Bioscience and Biotechnology NATURAL KILLER CELL EXPRESSING AN ANTI-COTININ CHEMERIC ANTIGEN RECEPTOR
MX2019011225A (es) * 2017-03-20 2020-01-21 Células t modificadas por el receptor de antígeno quimérico dirigidas a cs1 para el tratamiento de la amiloidosis al.
ES2963635T3 (es) * 2017-03-28 2024-04-01 Ohio State Innovation Foundation Vacunas de péptido PD1 humano y usos de las mismas
WO2018189360A1 (en) 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
KR20200027508A (ko) * 2017-07-07 2020-03-12 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 돌연변이된 cd28 공동자극 도메인을 갖는 키메라 항원 수용체
WO2019014624A1 (en) * 2017-07-14 2019-01-17 The Johns Hopkins University Engineered tsc2
TWI676483B (zh) * 2017-08-06 2019-11-11 強普生技股份有限公司 醫藥套組及其用途
WO2019069125A1 (en) * 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
US20200283501A1 (en) 2017-10-26 2020-09-10 Regents Of The University Of Minnesota Recombinant immune cells, methods of making, and methods of use
US12077598B2 (en) 2018-03-16 2024-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with mutated CD28 phosphorylation sites
CN112566643A (zh) 2018-06-12 2021-03-26 加利福尼亚大学董事会 用于治疗癌症的单链双特异性嵌合抗原受体
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020009868A1 (en) * 2018-07-03 2020-01-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-slamf7 chimeric antigen receptors
EP3818148A4 (en) * 2018-07-05 2022-09-28 Emory University TRANSDUCTION OF CONGENITAL IMMUNE COMPETENT CELLS USING AAV6
CN112469734A (zh) * 2018-08-03 2021-03-09 南京驯鹿医疗技术有限公司 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用
WO2020123716A1 (en) 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
MX2021010840A (es) 2019-03-08 2022-01-19 Obsidian Therapeutics Inc Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
KR102691932B1 (ko) 2019-04-03 2024-08-06 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
JP2022537670A (ja) 2019-06-12 2022-08-29 オブシディアン セラピューティクス， インコーポレイテッド Ｃａ２の組成物および調整可能な制御方法
EP3983537A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
SG11202111943UA (en) 2019-07-02 2021-11-29 Hutchinson Fred Cancer Res Recombinant ad35 vectors and related gene therapy improvements
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
EP4054602A4 (en) * 2019-11-08 2023-12-06 Mayo Foundation for Medical Education and Research EPHA3 TARGETED CAR-T CELLS FOR TREATING TUMORS
WO2022002919A1 (en) * 2020-06-29 2022-01-06 Julius-Maximilians-Universität Würzburg Slamf7 cars
CN114286691B (zh) 2020-08-06 2024-08-06 武汉思安医疗技术有限公司 Cs1-抗体和抗cs1-car-t细胞
WO2022063302A1 (zh) * 2020-09-25 2022-03-31 克莱格医学有限公司 免疫细胞活性调节
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
CN120344563A (zh) * 2022-12-02 2025-07-18 广州荔泰生物科技有限公司 人cs1 car-t细胞
WO2026006370A1 (en) * 2024-06-28 2026-01-02 Immunitybio, Inc. Anti-slamf7 antibodies and therapeutics

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
WO2010017103A2 (en) 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
EP2361263A1 (en) 2008-10-31 2011-08-31 Abbott Biotherapeutics Corp. Use of anti-cs1 antibodies for treatment of rare lymphomas
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
WO2011125015A2 (en) 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
ES2602743T3 (es) * 2010-09-08 2017-02-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
EP2643350A4 (en) * 2010-11-22 2015-01-07 Innate Pharma Sa TREATMENTS WITH NK CELL MODULATION AND METHOD FOR THE TREATMENT OF HEMATOLOGICAL MALIGNOMES
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013051718A1 (ja) * 2011-10-07 2013-04-11 国立大学法人三重大学 キメラ抗原受容体
PE20141937A1 (es) 2011-11-16 2014-12-18 Amgen Inc Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
CA2861491C (en) * 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
BR112015013193A2 (pt) 2012-12-07 2017-07-11 Solazyme Inc ácido nucleico recombinante, cassete de expressão, célula, método para obter óleo microbiano, óleo microbiano, e, método para obter óleo microbiano.
CN103224561A (zh) 2013-01-16 2013-07-31 天津大学 葡萄球菌肠毒素小分子抗体及制备方法及用途
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN105377897A (zh) * 2013-05-03 2016-03-02 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
KR20200131844A (ko) * 2018-03-16 2020-11-24 사이토이뮨 테라퓨틱스 인코퍼레이티드 이중특이적 항체 car 세포 면역요법

Also Published As

Publication number Publication date
WO2014179759A1 (en) 2014-11-06
US11845794B2 (en) 2023-12-19
KR20160003071A (ko) 2016-01-08
US20160075784A1 (en) 2016-03-17
HUE048312T2 (hu) 2020-07-28
US10227409B2 (en) 2019-03-12
BR112015027567A2 (pt) 2017-12-05
AU2014259675B2 (en) 2019-05-02
CA2910666A1 (en) 2014-11-06
HK1218925A1 (en) 2017-03-17
PL2992020T3 (pl) 2020-06-01
KR102098985B1 (ko) 2020-04-09
US10358494B2 (en) 2019-07-23
BR112015027567B1 (pt) 2024-02-20
JP2021177771A (ja) 2021-11-18
JP2019146579A (ja) 2019-09-05
PT2992020T (pt) 2020-02-28
ES2777940T3 (es) 2020-08-06
AU2019203823B2 (en) 2021-05-13
EP2992020A4 (en) 2016-12-28
EP2992020B1 (en) 2020-01-15
JP2016524598A (ja) 2016-08-18
CN115028735A (zh) 2022-09-09
AU2014259675A1 (en) 2015-11-12
US20170320941A1 (en) 2017-11-09
DK2992020T3 (da) 2020-02-10
IL242315B (en) 2020-07-30
EP3663320A1 (en) 2020-06-10
AU2019203823A1 (en) 2019-06-20
MX370173B (es) 2019-12-04
CN105377897A (zh) 2016-03-02
US20200002418A1 (en) 2020-01-02
JP7221338B2 (ja) 2023-02-13
EP2992020A1 (en) 2016-03-09
MX2015015182A (es) 2016-05-05

Similar Documents

Publication Publication Date Title
JP7221338B2 (ja) Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞
US20220135699A1 (en) Chimeric antigen receptor comprising interleukin-15 intracellular domain and uses thereof
JP7548950B2 (ja) キメラ抗原受容体およびその使用方法
US11840575B2 (en) Engineered immune cells targeting BCMA and their uses thereof
US11578113B2 (en) Compositions and methods of chimeric autoantibody receptor T cells
JP2019536452A (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
JP2021522790A (ja) ホスホリパーゼａ２受容体キメラ自己受容体ｔ細胞の組成物および方法
CN114929341A (zh) 用于治疗髓系恶性肿瘤的嵌合抗原受体
CA2910666C (en) Cs1-specific chimeric antigen receptor engineered immune effector cells
WO2026003364A1 (en) Chimeric coreceptors
HK1218925B (en) Cs1-specific chimeric antigen receptor engineered immune effector cells
HK40063360A (en) Compositions and methods of chimeric autoantibody receptor t cells

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190226

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190418

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20190507

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190606

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190920

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200107

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200310

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200910

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201013

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210105

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210112

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210216

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210303

R150 Certificate of patent or registration of utility model

Ref document number: 6856188

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250